PerkinElmer (NYSE: PKI) and Derma Sciences (NASDAQ:DSCI) are both computer and technology companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for PerkinElmer and Derma Sciences, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PerkinElmer 2 7 4 0 2.15
Derma Sciences 0 1 0 0 2.00

PerkinElmer presently has a consensus price target of $66.91, indicating a potential downside of 1.85%. Given PerkinElmer’s stronger consensus rating and higher possible upside, equities research analysts plainly believe PerkinElmer is more favorable than Derma Sciences.

Profitability

This table compares PerkinElmer and Derma Sciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PerkinElmer 16.80% 13.44% 6.85%
Derma Sciences -20.97% -17.10% -12.43%

Valuation & Earnings

This table compares PerkinElmer and Derma Sciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
PerkinElmer $2.14 billion 3.51 $416.05 million $3.31 20.60
Derma Sciences N/A N/A N/A ($0.40) -17.50

PerkinElmer has higher revenue and earnings than Derma Sciences. Derma Sciences is trading at a lower price-to-earnings ratio than PerkinElmer, indicating that it is currently the more affordable of the two stocks.

Dividends

PerkinElmer pays an annual dividend of $0.28 per share and has a dividend yield of 0.4%. Derma Sciences does not pay a dividend. PerkinElmer pays out 8.5% of its earnings in the form of a dividend.

Institutional and Insider Ownership

91.5% of PerkinElmer shares are owned by institutional investors. Comparatively, 58.9% of Derma Sciences shares are owned by institutional investors. 2.2% of PerkinElmer shares are owned by company insiders. Comparatively, 9.9% of Derma Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

PerkinElmer has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Derma Sciences has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Summary

PerkinElmer beats Derma Sciences on 10 of the 13 factors compared between the two stocks.

PerkinElmer Company Profile

PerkinElmer, Inc. is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets. It provides analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, lubricant, petrochemical and polymer industries. Its products include AAnalyst, Altus, Aquamatic, Avio, AxION, Clarus, DairyGuard, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, Cell carrier and cell::explorer. The Diagnostics segment is focused on reproductive health, emerging market diagnostics and applied genomics. Its products include AutoDELFIA, BACS-on-Beads, Bioo Scientific, BoBs, Datalytix, Dexela, Dexela CMOS FPDs, Evolution, ViaCord, and Zephyr.

Derma Sciences Company Profile

Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company’s advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company’s traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.